RJA
AZN icon

Raymond James & Associates’s AstraZeneca AZN Stock Holding History

Raymond James & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,600
Closed -$1.48M – 3969
2024
Q1 		$1.48M Buy
+10,600
New +$1.4M ﹤0.01% 2349

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's AZN Position: Q3 2024 in Review

Raymond James & Associates reduced its AstraZeneca (AZN) stake by 5.7% in Q3 2024, selling an estimated $11.9M and leaving 1,214,635 shares worth $189M. The position accounts for 0.12% of the portfolio, ranked #160.

Raymond James & Associates first reported a position in AZN in Q2 2013 and has held it in 46 quarters since. The position peaked at $201M in Q2 2024. 1,229 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

  • Raymond James & Associates held 1,214,635 shares of AstraZeneca worth $189M as of Q3 2024.
  • Raymond James & Associates sold 73,733 AstraZeneca shares in Q3 2024, an estimated $11.9M.
  • AstraZeneca made up 0.12% of Raymond James & Associates's portfolio in Q3 2024, its #160 holding.
  • Raymond James & Associates first reported a position in AstraZeneca in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's AstraZeneca position peaked at $201M in Q2 2024.
  • 1,229 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.